Loading clinical trials...
Loading clinical trials...
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB118C Injection in Patients With Advanced Solid Tumors
Conditions
Interventions
MHB118C for Injection
Locations
1
China
Shanghai Chest Hospital
Shanghai, China
Start Date
March 31, 2025
Primary Completion Date
March 1, 2029
Completion Date
March 1, 2031
Last Updated
July 1, 2025
NCT06658951
NCT07293754
NCT06717750
NCT06380309
NCT07292402
NCT07050641
Lead Sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions